Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer based in Kfar Saba, Israel, for the month of December 2018. The filing incorporates by reference a press release dated December 17, 2018, regarding a grant application approval by the Israel Innovation Authority (KORIL).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory milestone rather than financial performance data.
Material Changes
The primary material event reported is the approval of Cellect's grant application by KORIL. No financial comparisons to prior periods are included in this document.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release by reference, though the specific content of these statements is not detailed in the provided text. No specific risks, contingencies, or unusual items are described beyond the grant approval context.
Investor Verification Checklist
- Verify the specific terms and funding amount of the KORIL grant approval referenced in the press release.
- Review the full text of the "Forward Looking Statements" incorporated by reference to understand management's outlook.
- Confirm the status of the company's cash position and burn rate in subsequent filings, as this 6-K contains no financial data.